Loading Daily Peptide Guide…
A structured view of recovery, connective-tissue and mitochondrial research—clearly separated from unverified performance claims.
24 records shown. Listed A–Z. Study findings depend on the population and indication; this is not a ranking or recommendation.
| Compare | Compound | Regulatory segment | Research context | Evidence and limits |
|---|---|---|---|---|
| Apelin analogue programsAPJ agonist programs | Clinical pipeline | A group of early research programs studying apelin-related signaling.Catalog tags: Phase 1 / early human evidence · Preclinical animal evidence | This category does not identify one approved product or an established human benefit. | |
| ARA-290Cibinetide | Clinical pipeline | Also called cibinetide, an investigational peptide studied in small-fiber nerve damage.Catalog tags: Phase 2 human evidence · Phase 1 / early human evidence · Preclinical animal evidence | Small studies in sarcoidosis-related nerve damage found signals worth further study; they do not establish broad nerve-repair benefits. | |
| BimagrumabBYM338 | Clinical pipeline | An investigational antibody studied for muscle and body-composition conditions.Catalog tags: Phase 2 human evidence | More lean mass does not necessarily mean better strength or function. This is an antibody, not a small peptide vial. | |
| BPC-157Body protection compound 157 | Unapproved / grey-market context | A research peptide often marketed for gut, tendon and injury recovery.Catalog tags: Preclinical animal evidence · Laboratory / in-vitro evidence · Anecdotal report · Marketing claim | Reliable human recovery benefits have not been established. FDA material identifies gaps in safety and concerns about peptide impurities. | |
| CJC-1295CJC-1295 with DAC | Unapproved / grey-market context | An investigational growth-hormone-releasing hormone analogue.Catalog tags: Phase 1 / early human evidence · Anecdotal report · Marketing claim | Those hormone measurements do not establish muscle or anti-aging benefits. Products sold as no-DAC are not the same studied formulation. | |
| ElamipretideSS-31 · Forzinity | Approved therapeutic | SS-31 is the research name commonly associated with elamipretide, the ingredient in Forzinity.Catalog tags: Phase 3 / randomized human evidence · Phase 2 human evidence | Forzinity has a narrow accelerated US approval for Barth syndrome in patients weighing at least 30 kg. This does not validate general anti-aging or recovery claims. | |
| GHK-CuCopper peptide · Copper tripeptide-1 | Cosmetic / topical | A copper-binding peptide used in cosmetic products and discussed in skin-repair research.Catalog tags: Laboratory / in-vitro evidence · Preclinical animal evidence · Marketing claim | Topical cosmetic evidence cannot establish the safety or benefit of injections; FDA flags concerns for injectable GHK-Cu. | |
| Ghrelin receptor agonist programsGHSR agonist programs | Clinical pipeline | A research category for treatments targeting appetite and related hormone signals.Catalog tags: Phase 2 human evidence · Phase 1 / early human evidence | Studies in illness-related appetite loss should not be treated as evidence for healthy-person enhancement. | |
| GHRP-2Pralmorelin · Growth hormone-releasing peptide 2 | Unapproved / grey-market context | Also called pralmorelin, a peptide studied for its ability to stimulate growth-hormone release.Catalog tags: Phase 1 / early human evidence · Anecdotal report · Marketing claim | A diagnostic or short-term hormone response is different from evidence for long-term enhancement use. | |
| GHRP-6Growth hormone-releasing peptide 6 | Unapproved / grey-market context | A growth-hormone-releasing peptide also associated with appetite effects.Catalog tags: Phase 1 / early human evidence · Anecdotal report · Marketing claim | Appetite or hormone changes do not establish a favorable long-term balance of benefits and harms. | |
| Growth-hormone secretagogue pathway assetsGHS pathway class | Clinical pipeline | A group of research treatments that affect the release of growth hormone.Catalog tags: Phase 2 human evidence · Phase 1 / early human evidence · Preclinical animal evidence | A measured hormone increase is not proof of improved muscle, recovery or longevity. | |
| HexarelinExamorelin | Unapproved / grey-market context | Also called examorelin, a growth-hormone secretagogue studied for endocrine effects.Catalog tags: Phase 1 / early human evidence · Preclinical animal evidence · Anecdotal report · Marketing claim | Short-term endocrine studies do not establish lasting recovery, strength or longevity benefits. | |
| Incretin multi-agonist programsGLP-1 multi-agonist class · Incretin combination pathway class | Clinical pipeline | A category of treatments combining gut-hormone pathways for metabolic research.Catalog tags: Phase 3 / randomized human evidence · Phase 2 human evidence · Phase 1 / early human evidence | These are not interchangeable products; receptor targets and clinical evidence differ. | |
| IpamorelinIpamorelin acetate | Unapproved / grey-market context | A research peptide that stimulates growth-hormone release.Catalog tags: Phase 1 / early human evidence · Preclinical animal evidence · Anecdotal report · Marketing claim | An acute hormone response does not establish useful body-composition changes or safe long-term use. | |
| MecaserminIncrelex · Recombinant IGF-1 | Approved therapeutic | A replacement form of IGF-1 used for a narrowly defined growth disorder.Catalog tags: Phase 3 / randomized human evidence | It is not a general muscle-building medicine; the diagnostic criteria and risks are specific. | |
| MOTS-cMitochondrial open reading frame of 12S rRNA-c | Unapproved / grey-market context | A mitochondria-derived peptide studied in metabolism and exercise-related research.Catalog tags: Preclinical animal evidence · Laboratory / in-vitro evidence · Anecdotal report · Marketing claim | Laboratory findings do not establish improved endurance, fat loss or safety from injecting a purchased vial. | |
| Myostatin / activin-pathway inhibitorsActRII pathway class · Myostatin inhibitor class | Clinical pipeline | A research category covering several different muscle-regulatory treatments, not one medicine.Catalog tags: Phase 2 human evidence · Phase 1 / early human evidence · Preclinical animal evidence | Evidence belongs to each molecule and trial; a class label cannot define a dose, vial or expected result. | |
| RetatrutideLY3437943 | Clinical pipeline | An investigational medicine being studied for obesity, type 2 diabetes and related conditions.Catalog tags: Phase 3 / randomized human evidence · Phase 2 human evidence · Phase 1 / early human evidence | Phase 3 results have been reported, but it is not FDA approved. Triple agonist is the accurate term; GLP3 is an informal nickname, not a receptor name. | |
| SemaglutideOzempic · Wegovy | Approved therapeutic | A medicine used in specific products for type 2 diabetes and weight management.Catalog tags: Phase 3 / randomized human evidence | The approved uses differ between Ozempic, Wegovy and Rybelsus; their formulations are not interchangeable. | |
| SermorelinGHRH(1-29) | Unapproved / grey-market context | A growth-hormone-releasing hormone analogue with a history of medical use and current product-specific questions.Catalog tags: Phase 1 / early human evidence · Case report · Anecdotal report · Marketing claim | Historical product approvals do not automatically apply to current compounded products or wellness claims. | |
| SomatropinRecombinant human growth hormone · rhGH | Approved therapeutic | A manufactured version of human growth hormone used for specific diagnosed conditions.Catalog tags: Phase 3 / randomized human evidence | Treatment of hormone deficiency does not establish benefits or safety for healthy-person anti-aging use. | |
| TB-500Thymosin beta-4 fragment | Unapproved / grey-market context | A commercial research label associated with thymosin beta-4-related products.Catalog tags: Preclinical animal evidence · Laboratory / in-vitro evidence · Anecdotal report · Marketing claim | TB-500 and full-length thymosin beta-4 must not be assumed identical. A seller's label does not prove molecular identity or human benefit. | |
| TesamorelinEgrifta · TH9507 | Approved therapeutic | A medicine for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.Catalog tags: Phase 3 / randomized human evidence | It is not approved as a general weight-loss treatment. Increased IGF-1, glucose intolerance and fluid retention are relevant concerns. | |
| TirzepatideMounjaro · Zepbound | Approved therapeutic | A medicine used in Mounjaro for type 2 diabetes and Zepbound for specific weight-related conditions.Catalog tags: Phase 3 / randomized human evidence | Trials of the approved products do not establish the quality of a separately purchased research vial. |